title: Outcome of patients without any immunosuppressive therapy after renal allograft failure.
abstract: Continuation of low-dose maintenance immunosuppressive therapy in end-stage renal allografts (ESRAs) that are left in situ is controversial. We studied the outcome of 85 patients (mean age 33.3 +/- 13.4 and range of 12-56 years) on hemodialysis with ESRAs, and without immunosuppressive therapy in our center from July 1991 to July 2003. Twelve (14.1%) study patients underwent allograft nephrectomy within a mean interval of 44.5 months after graft failure. The rest of the patients remained stable without fever, hematuria, graft tenderness, or localized edema during a mean interval of 46.5 +/- 45.2 months of follow-up. These results are promising and suggest that maintenance immuno-suppressive therapy in patients with ESRAs and on dialysis may not be necessary to avoid allograft nephrectomy. Prospective studies are warranted to substantiate these results.
authors: Department of Nephrology, Khorshid Hospital, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran. af_emami@med.mui.ac.ir
authors: Afsoon Emami
authors: AE
authors: Naini
authors: Ali Amini
authors: AA
authors: Harandi
authors: Pooya
authors: P
authors: Daemi
authors: Rozbeh
authors: R
authors: Kosari
authors: Manochehr
authors: M
authors: Gharavi
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D008875:Middle Aged; D009392:Nephrectomy; D006435:Renal Dialysis; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D017211:Treatment Failure
chemical_list: D007166:Immunosuppressive Agents